Nonclinical Safety Considerations for the Development of Pediatric-First Drugs An Industry View
2016
This paper provides considerations on approaches to the development of medicines initially developed for pediatric use (ie, “pediatric-first” or “pediatric-only” drugs). The most common development approach for these types of medicines involves a first-in-human (FIH) clinical trial with healthy adult volunteers to assess safety and tolerability. This approach generally requires nonclinical repeat-dose studies in adult animals; safety pharmacology and in vivo genetic toxicology studies in adult animals are also performed for small-molecule drugs. Additional studies in juvenile animals may be required prior to clinical trials in pediatric patients, on a case-by-case basis. In this paradigm, the starting dose for pediatric patients is primarily driven by modeling from the adult pharmacokinetic assessment and pharmacology data. A second development approach is where the FIH clinical trial is conducted in pediatric patients. This approach is generally supported by repeat-dose studies in juvenile animals, with ...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
3
References
1
Citations
NaN
KQI